Cipher Capital’s Nektar Therapeutics NKTR Stock Holding History

Cipher Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-967	Closed	-$46K	–	589
2022 Q3	$46K	Buy	+967	New	+$57.5K	0.01%	414

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cipher Capital's NKTR Position: Q4 2022 in Review

Cipher Capital sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 967 shares — an estimated $46K sold.

Cipher Capital first reported a position in NKTR in Q3 2022 and held it in 1 quarter. The position peaked at $46K in Q3 2022. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

Cipher Capital reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
Cipher Capital sold 967 Nektar Therapeutics shares in Q4 2022, an estimated $46K.
Cipher Capital first reported a position in Nektar Therapeutics in Q3 2022 and held it in 1 quarter.
Cipher Capital's Nektar Therapeutics position peaked at $46K in Q3 2022.
214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Cipher Capital's 13F filing for Q4 2022, filed 13 Feb 2023.